Proteomics to start selling in France

Proteomics (ASX:PIQ) says Eurobio Scientific has been chosen as the exclusive distributor for the PromarkerD predictive test for diabetic kidney disease in France.

Eurobio, a prominent French company specialising in in-vitro diagnostics (IVD), has a strong reputation for marketing specialty diagnostic tests to various clinical laboratories, both public and private.

In France, where approximately 3.9 million adults — about 8.6% of the population — live with diabetes, the introduction of PromarkerD could play a crucial role, says PIQ.

This innovative test was designed to predict the risk of diabetic kidney disease (DKD) in individuals with diabetes. Given that France also faces one of Europe’s highest rates of end-stage renal disease, early detection provided by PromarkerD is essential.

Proteomics’s CEO, Dr Richard Lipscombe, believes that Eurobio’s extensive distribution network across France will facilitate efficient access to the PromarkerD test for healthcare providers.

“Eurobio Scientific’s strong relationships with key stakeholders, robust market knowledge and local expertise will drive demand for our test in this important market.”


Recce granted ethical approval for clinical trials

Recce Pharma (ASX:RCE) has received approval to expand its RECCE 327 Gel clinical trials for treating various bacterial skin infections.

This approval allows the company to centralise and broaden its Phase II trials, focusing on conditions like Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

The trials, approved by the Human Research Ethics Committee, will be conducted at Barwon Health and other healthcare providers in Australia starting Q3 2024. This marks a significant step in testing R327’s potential as a topical treatment for complicated skin and soft tissue infections.

Previous tests under Australia’s TGA Special Access Scheme have shown promising results against infected burn wounds and diabetic foot infections.

Recce says it aims to gather crucial data on R327’s effectiveness through this open-label study, evaluating both single and multiple doses of the gel.

ABSSSI covers a range of serious skin infections, including diabetic foot and wound infections, making this research vital for addressing unmet medical needs.


EMV gets $1.25m grant

Meanwhile, EMVision Medical Devices (ASX: EMV) announced the establishment of its pilot commercial production line and the receipt of a final non-dilutive cash payment totalling $1,250,000 under the Modern Manufacturing Initiative (MMI) grant program.

The Federal Government had earlier awarded EMVision $5 million through the MMI Medical Products Translation stream to support the establishment of commercial production for the emu point-of-care brain scanner.

Located at EMVision’s Macquarie Park facilities, the new production line is initially capable of producing, testing, and releasing approximately one emu device per week.

With modest expansions in personnel, the line is projected to increase the company’s capacity to assemble, test, and release up to three emu brain scanners per week.